Coalition Says Bayh-Dole Not For Cutting Drug Costs
Law360 (February 4, 2021, 8:17 PM EST) -- The branded-drug industry, top research universities and other organizations on Thursday said they've banded together to return the Bayh-Dole Act to its original purpose, which they say is expanding innovation and commercialization, not reining in drug prices.
The Bayh-Dole Coalition is the extension of the Bayh-Dole 40 Coalition, a group that came together last year during the act's 40th anniversary. Through webinars and articles, the group has sought to move the focus of Bayh-Dole from price control to commercialization.
"The Bayh-Dole Act has been a catalyst for innovation in the United States for more than 40 years," Executive Director Joseph P. Allen said...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!